Panitumumab, sold under the brand name Vectibix, is a fully human monoclonal antibody specific to the epidermal growth factor receptor (also known as...
16 KB (1,421 words) - 15:40, 14 July 2024
(FDA) updated the labels of two anti-EGFR monoclonal antibody drugs (panitumumab (Vectibix) and cetuximab (Erbitux)) indicated for treatment of metastatic...
26 KB (2,420 words) - 06:06, 17 August 2024
nerve palsy Anti-cancer treatments such as erlotinib, cetuximab, and panitumumab, which block the function of EGFR (the epidermal growth factor receptor)...
3 KB (220 words) - 20:32, 27 August 2024
often[citation needed] combined with bevacizumab, aflibercept, cetuximab or panitumumab to improve efficacy and response rate. In the short term, irinotecan...
4 KB (411 words) - 21:05, 6 May 2024
As of 2006, KRAS mutation was predictive of a very poor response to panitumumab (Vectibix) and cetuximab (Erbitux) therapy in colorectal cancer. As of...
45 KB (5,079 words) - 06:39, 25 June 2024
2006: In April, Amgen acquired Abgenix, the developer of Vectibix (panitumumab), a treatment developed for certain patients with metastatic colorectal...
96 KB (7,758 words) - 18:19, 12 September 2024
Cetuximab Dostarlimab Gemtuzumab ozogamicin Ipilimumab Nivolumab Ofatumumab Panitumumab Pembrolizumab Ranibizumab Rituximab Trastuzumab Monoclonal antibodies...
49 KB (4,964 words) - 04:02, 9 August 2024
Depatuxizumab mafodotin Futuximab Imgatuzumab Matuzumab Necitumumab Nimotuzumab Panitumumab Zalutumumab ErbB2/HER2 Agonists: Unknown/none Antibodies: Ertumaxomab...
121 KB (13,799 words) - 18:31, 13 September 2024
Depatuxizumab mafodotin Futuximab Imgatuzumab Matuzumab Necitumumab Nimotuzumab Panitumumab Zalutumumab ErbB2/HER2 Agonists: Unknown/none Antibodies: Ertumaxomab...
31 KB (3,430 words) - 05:24, 28 August 2024
conventional antibodies like trastuzumab (targeting HER2/neu), cetuximab and panitumumab (both targeting the EGF receptor), using the BiTE approach. As of 2009[update]...
9 KB (1,472 words) - 21:30, 9 September 2024
colorectal cancer and squamous cell carcinoma of the head and neck. Panitumumab also targets the EGFR. It is approved for the use in the treatment of...
20 KB (2,234 words) - 01:21, 22 July 2024
Depatuxizumab mafodotin Futuximab Imgatuzumab Matuzumab Necitumumab Nimotuzumab Panitumumab Zalutumumab ErbB2/HER2 Agonists: Unknown/none Antibodies: Ertumaxomab...
13 KB (1,177 words) - 02:19, 4 September 2024
Depatuxizumab mafodotin Futuximab Imgatuzumab Matuzumab Necitumumab Nimotuzumab Panitumumab Zalutumumab ErbB2/HER2 Agonists: Unknown/none Antibodies: Ertumaxomab...
149 KB (15,717 words) - 22:05, 8 September 2024
Depatuxizumab mafodotin Futuximab Imgatuzumab Matuzumab Necitumumab Nimotuzumab Panitumumab Zalutumumab ErbB2/HER2 Agonists: Unknown/none Antibodies: Ertumaxomab...
92 KB (8,671 words) - 18:15, 17 August 2024
the ICG to antibodies such as daclizumab (Dac), trastuzumab (Tra), or panitumumab (Pan). ICG and laser therapy has been shown to kill human pancreatic...
27 KB (2,788 words) - 11:29, 6 August 2024
Depatuxizumab mafodotin Futuximab Imgatuzumab Matuzumab Necitumumab Nimotuzumab Panitumumab Zalutumumab ErbB2/HER2 Agonists: Unknown/none Antibodies: Ertumaxomab...
68 KB (5,999 words) - 20:41, 31 August 2024
of which the three FDA approved ones are aflibercept, cetuximab and panitumumab. The primary difference in the approach to low stage rectal cancer is...
145 KB (15,781 words) - 22:45, 30 August 2024
factor (CTGF) idiopathic pulmonary fibrosis (IPF), pancreatic cancer Panitumumab Vectibix mab human epidermal growth factor receptor (EGFR) Y colorectal...
136 KB (4,020 words) - 07:14, 15 August 2024
Depatuxizumab mafodotin Futuximab Imgatuzumab Matuzumab Necitumumab Nimotuzumab Panitumumab Zalutumumab ErbB2/HER2 Agonists: Unknown/none Antibodies: Ertumaxomab...
16 KB (1,784 words) - 04:08, 6 January 2024
Depatuxizumab mafodotin Futuximab Imgatuzumab Matuzumab Necitumumab Nimotuzumab Panitumumab Zalutumumab ErbB2/HER2 Agonists: Unknown/none Antibodies: Ertumaxomab...
46 KB (5,344 words) - 03:26, 11 August 2024
Depatuxizumab mafodotin Futuximab Imgatuzumab Matuzumab Necitumumab Nimotuzumab Panitumumab Zalutumumab ErbB2/HER2 Agonists: Unknown/none Antibodies: Ertumaxomab...
25 KB (2,086 words) - 02:24, 16 July 2024
Depatuxizumab mafodotin Futuximab Imgatuzumab Matuzumab Necitumumab Nimotuzumab Panitumumab Zalutumumab ErbB2/HER2 Agonists: Unknown/none Antibodies: Ertumaxomab...
22 KB (1,994 words) - 04:41, 3 January 2024
already been available in the market, such as cetuximab (Erbitux) and panitumumab (Vectibix), both of which are directed against HER1. However, cancer...
29 KB (3,349 words) - 19:04, 30 July 2024
mutation if it is combined with an anti-EGFR antibody such as cetuximab or panitumumab. Brigatinib is an inhibitor of ALK and mutated EGFR. ALK was first identified...
10 KB (796 words) - 12:29, 5 August 2024
Depatuxizumab mafodotin Futuximab Imgatuzumab Matuzumab Necitumumab Nimotuzumab Panitumumab Zalutumumab ErbB2/HER2 Agonists: Unknown/none Antibodies: Ertumaxomab...
24 KB (1,710 words) - 19:18, 30 August 2024
AKT pathway. Panitumumab is a human mAb with high EGFR affinity that blocks ligand-binding to induce EGFR internalization. Panitumumab efficacy has been...
24 KB (2,736 words) - 00:12, 28 November 2023
number NCT02448810 for "Phase 2a Study of BAX69 and 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer"...
3 KB (187 words) - 10:33, 7 June 2024
Depatuxizumab mafodotin Futuximab Imgatuzumab Matuzumab Necitumumab Nimotuzumab Panitumumab Zalutumumab ErbB2/HER2 Agonists: Unknown/none Antibodies: Ertumaxomab...
20 KB (1,623 words) - 12:42, 5 August 2024
Depatuxizumab mafodotin Futuximab Imgatuzumab Matuzumab Necitumumab Nimotuzumab Panitumumab Zalutumumab ErbB2/HER2 Agonists: Unknown/none Antibodies: Ertumaxomab...
42 KB (3,935 words) - 04:01, 30 April 2024
Depatuxizumab mafodotin Futuximab Imgatuzumab Matuzumab Necitumumab Nimotuzumab Panitumumab Zalutumumab ErbB2/HER2 Agonists: Unknown/none Antibodies: Ertumaxomab...
5 KB (412 words) - 23:17, 19 June 2023